SM
AIMT

Sabby Management’s Aimmune Therapeutics AIMT Stock Holding History

Sabby Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,629
Closed -$213K – 208
2017
Q4 		$213K Buy
+5,629
New +$182K 0.02% 123

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Sabby Management's AIMT Position: Q1 2018 in Review

Sabby Management sold out of Aimmune Therapeutics (AIMT) in Q1 2018, closing a stake of 5,629 shares — an estimated $213K sold.

Sabby Management first reported a position in AIMT in Q4 2017 and held it in 1 quarter. The position peaked at $213K in Q4 2017. 155 funds tracked by Wall St. Rank hold AIMT as of Q1 2018.

  • Sabby Management reported no remaining Aimmune Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Sabby Management sold 5,629 Aimmune Therapeutics shares in Q1 2018, an estimated $213K.
  • Sabby Management first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 1 quarter.
  • Sabby Management's Aimmune Therapeutics position peaked at $213K in Q4 2017.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.